S
Siti M. Janib
Researcher at University of Southern California
Publications - 14
Citations - 1517
Siti M. Janib is an academic researcher from University of Southern California. The author has contributed to research in topics: Fusion protein & Drug delivery. The author has an hindex of 10, co-authored 13 publications receiving 1358 citations. Previous affiliations of Siti M. Janib include Malaysian Nuclear Agency.
Papers
More filters
Journal ArticleDOI
Imaging and drug delivery using theranostic nanoparticles
TL;DR: State-of-the-art nanoparticles from a therapeutic and a diagnostic perspective are reviewed and challenges in bringing these fields together are discussed and potential advantages that will spur the development of theranostic agents are discussed.
Journal ArticleDOI
Environmentally responsive peptides as anticancer drug carriers
TL;DR: This review explores potential microenvironmental physiology indicative of tumors and peptides that have demonstrated an ability to target and deliver to these signals.
Journal ArticleDOI
Biodegradation of elastin‐like polypeptide nanoparticles
TL;DR: It is demonstrated that ELP nanoparticles can be degraded by two model proteases and that comparable proteolysis occurs after cell uptake into a transformed culture of murine hepatocytes.
Journal ArticleDOI
A quantitative recipe for engineering protein polymer nanoparticles
Siti M. Janib,M. F. Pastuszka,Suhaas Aluri,Zoë Folchman-Wagner,Pang-Yu Hsueh,Pu Shi,Yi-An Lin,Honggang Cui,John Andrew MacKay +8 more
TL;DR: It is reported that a surprisingly high core molecular weight is required for stable nanoparticle formation; furthermore, nanoparticle size depends on polymer molecular weight.
Journal ArticleDOI
Design and cellular internalization of genetically engineered polypeptide nanoparticles displaying adenovirus knob domain
TL;DR: The results are a proof-of-principal that large fusion proteins (>10 kDa) can be assembled by diblock ELPs without the need for bioconjugate chemistry, which greatly simplifies the design and evaluation of targeted drug carriers.